Atezolizumab is a monoclonal antibody that binds to PD-L1, blocking its binding to and activation of PD-1, which is expressed on activated T-cells, that may enhance the T-cell-mediated immune response towards the tumour and reverse T-cell inactivation [159]. Here, PDCD1 is linked to neoplasm.